EU Accepts Sanofi Remedies, Ends Antitrust Probe Over Vaccine Marketing

The European Commission has accepted the remedial commitments submitted by Sanofi to close its antitrust investigation into the marketing of its Efluelda influenza vaccine. The EU's competition authority stated it adopted Sanofi's proposed corrective plan, which addresses potential adverse effects on rival influenza vaccines from Australian CSL, thereby eliminating regulatory concerns. The Commission noted that these legally binding commitments will require Sanofi to rectify past promotional statements.